Press Release: Genexpath joins Biovalley Group
Biovalley announces the acquisition of Genexpath to strengthen its expertise in molecular diagnostics and hemato-oncology
Nanterre, July 29, 2025 – Biovalley Group, a leading European player in the distribution and development of solutions for research and diagnostics, announces the strategic acquisition of Genexpath, a company specialized in molecular diagnostic solutions for lymphomas and sarcomas.
Founded in Rouen, Genexpath has emerged as an innovative force thanks to its in vitro diagnostic tests based on RT-MLPSeq technology, developed by the research team of the Henri Becquerel Center (Inserm U1245) led by Professor Fabrice Jardin. These tests allow for precise classification of B- and T-cell lymphomas, as well as rapid detection of fusion transcripts in sarcomas. Combined with proprietary bioinformatics platforms, these solutions significantly accelerate diagnosis and support clinical decision-making.
"The integration of Genexpath is fully aligned with our strategy to strengthen our oncology and hematology portfolio. Their technology enhances our offering of innovative, high clinical value solutions"
Tushendan Rasiah, CEO of Biovalley Group.
With this acquisition, Biovalley continues its expansion in the field of in vitro diagnostics, while reaffirming its commitment to supporting French biotechnology and unlocking new growth opportunities in Europe and globally.
Genexpath will maintain its base in Normandy, continue the collaboration with Normandie Valorisation and Centre Henri Becquerel, with development plans to expand its offering to other disease areas and strengthen its presence both in France and internationally.